Sequent Scientific Ltd (SEQUENT) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 512529 | NSE: SEQUENT | Pharmaceuticals & Drugs | Small Cap

Sequent Scientific Share Price

199.65 -8.00 -3.85%
as on 05-Dec'25 12:17

Sequent Scientific Ltd (SEQUENT) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 512529 | NSE: SEQUENT | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Sequent Scientific

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Sequent Scientific stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
125.63
Market Cap:
5,252.5 Cr.
52-wk low:
111
52-wk high:
260.3

Is Sequent Scientific Ltd an attractive stock to invest in?

1. Is Sequent Scientific Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sequent Scientific Ltd is a average quality company.

2. Is Sequent Scientific Ltd undervalued or overvalued?

The key valuation ratios of Sequent Scientific Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Sequent Scientific Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sequent Scientific Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Sequent Scientific:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sequent Scientific Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 2.5%1.1%4.8%9.2%12.6%16.2%7%-9.7%-0.6%9.3%-
Value Creation
Index
-0.8-0.9-0.7-0.3-0.10.2-0.5-1.7-1.0-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 6066848481,0391,1791,3621,4131,4211,3701,5511,658
Sales YoY Gr.-12.8%24%22.6%13.5%15.5%3.8%0.6%-3.6%13.3%-
Adj EPS -0.8-0.10.22.2341.5-4.5-0.51.11.7
YoY Gr.-NANA1042.1%36.4%35.5%-63.6%-408.9%NANA-
BVPS (₹) 38.739.425.927.927.1292625.823.224.332
Adj Net
Profit
-19.6-1.64.753.673.499.636.4-112-12.126.742
Cash Flow from Ops. -0.1-7.245.211611511530.616.830.683.4-
Debt/CF from Ops. -5782.5-57.86.72.83210.323.714.85.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 11%5.6%3.2%13.3%
Adj EPS NA-18.4%-9.8%NA
BVPS-5.1%-2.2%-2.2%4.6%
Share Price -1.4% 4.6% 27.4% -0.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-3.8-0.20.67.910.514.15.1-16.2-1.83.95.9
Op. Profit
Mgn %
9.68.510.312.814.915.77.81.75.610.811.4
Net Profit
Mgn %
-2.9-0.61.767.382.8-8-0.42.42.5
Debt to
Equity
0.30.40.50.50.50.30.50.60.80.70.3
Working Cap
Days
227275246206190179196199208198100
Cash Conv.
Cycle
799389797380951021069545

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 5.90%

Debt to equity has declined versus last 3 years average to 0.73

Sales growth is good in last 4 quarters at 14.50%

Sales growth has been subdued in last 3 years 3.17%

Net Profit has been subdued in last 3 years -9.84%

Latest Financials - Sequent Scientific Ltd.

Standalone Consolidated
TTM EPS (₹) 0.5 1.7
TTM Sales (₹ Cr.) 154 1,658
BVPS (₹.) 46.7 32
Reserves (₹ Cr.) 1,131 759
P/BV 4.45 6.49
PE 389.36 125.63
From the Market
52 Week Low / High (₹) 111.00 / 260.30
All Time Low / High (₹) 0.40 / 336.40
Market Cap (₹ Cr.) 5,252
Equity (₹ Cr.) 50.6
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Sequent Scientific:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Sequent Scientific - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Sequent Scientific

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales6066848481,0391,1791,3621,4131,4211,3701,551
Operating Expenses 5516417659141,0091,1521,3031,4091,3081,393
Manufacturing Costs997074101108125128129109101
Material Costs299357462543605695793834760812
Employee Cost 87106114146165187231258251281
Other Costs 67107115125131145152187189199
Operating Profit 5543831251702101091261159
Operating Profit Margin (%) 9.1%6.3%9.8%12.0%14.4%15.4%7.7%0.8%4.5%10.2%
Other Income 131117910101161118
Interest 38283333362416364861
Depreciation 46404142515152566266
Exceptional Items 00-200-90-65-17-5
Profit Before Tax -15-1424599413753-138-5544
Tax 3-113212328-16-2512
Profit After Tax -18-1410578210445-122-3032
PAT Margin (%) -3.0%-2.0%1.2%5.5%7.0%7.7%3.2%-8.6%-2.2%2.1%
Adjusted EPS (₹)-0.8-0.617.32.02.83.81.7-4.9-1.40.9
Dividend Payout Ratio (%)0%0%1%10%0%13%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 922961630688673720645642579608
Share Capital 48494949505050505050
Reserves 874912581638623670595593529558
Minority Interest2173740454948505666
Debt267360256275297197282332389435
Long Term Debt21116510414815094122150143274
Short Term Debt56195152127147103160182246161
Trade Payables144203160209220227258244251257
Others Liabilities 203362259189228251254214256207
Total Liabilities 1,5381,9041,3431,4021,4631,4431,4871,4841,5311,572

Fixed Assets

Gross Block6447905826387627538259409591,003
Accumulated Depreciation57105106140186218261335367417
Net Fixed Assets 586684476498577536564605592586
CWIP 24331823133112551616
Investments 4284282391801718338040
Inventories135161159200219264348346346385
Trade Receivables192255258278319346329341336363
Cash Equivalents 25474272765659427069
Others Assets 1482961501518812713694168153
Total Assets 1,5381,9041,3431,4021,4631,4431,4871,4841,5311,572

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -0-74511611511531173183
PBT -14-17446599414553-138-5544
Adjustment 84123-31484918494221145155
Changes in Working Capital -71-104-78-28-58-71-89-52-46-88
Tax Paid 1-9-91-12-44-27-15-14-28
Cash Flow From Investing Activity -316-1167-68-7210-96-65-6-25
Capex -96-75-45-24-40-45-31-75-12-29
Net Investments -11974812-3953-4124-82
Others -101-484-5672-23-14142
Cash Flow From Financing Activity 309147-57-20-43-1396732-1-61
Net Proceeds from Shares 540411221011007
Net Proceeds from Borrowing -2920-51450-743622-480
Interest Paid -40-37-33-26-33-23-16-36-45-51
Dividend Paid 00-50-50-12-0-0-2
Others -16212431-40-7-53484648-95
Net Cash Flow -724-5280-142-1623-2

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-3.67-1.471.288.6312.06156.56-18.95-4.855.44
ROCE (%)2.51.054.849.2412.5916.247.01-9.71-0.69.3
Asset Turnover Ratio0.510.40.520.770.840.960.980.980.941.03
PAT to CFO Conversion(x)N/AN/A4.52.041.41.110.69N/AN/A2.59
Working Capital Days
Receivable Days9011811093908785848880
Inventory Days67786962646478879084
Payable Days143178144124130118112110119114

Sequent Scientific Ltd Stock News

Sequent Scientific Ltd FAQs

The current trading price of Sequent Scientific on 05-Dec-2025 12:17 is ₹199.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Sequent Scientific stood at ₹5,252.5.
The latest P/E ratio of Sequent Scientific as of 04-Dec-2025 is 389.4.
The latest P/B ratio of Sequent Scientific as of 04-Dec-2025 is 4.45.
The 52-week high of Sequent Scientific is ₹260.3 and the 52-week low is ₹111.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sequent Scientific is ₹153.7 ( Cr.) .

About Sequent Scientific Ltd

P I Drugs & Pharmaceuticals Ltd. established in 1991 is a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.

P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the formulation belonging to anthelmintic & anti-parasitic segment.

In September 2007 PI Drugs purchased the pharma division of Transchem Limited.

The company is engaged in the business of human health & animal health and enjoys high Image for distribution in domestic as well as international markets.

They have a specialized and dedicated WHO - GMP accredited manufacturing plant for the manufacture of API's. It exports to all major markets like Europe, South America, Australia, Asia and Africa.

They started with the introduction of Albendazole and has developed core competency in chemistry of Benzimadazole in very short time.

Product range of the company includes:

Human / Veterinary Formulations

  • Diminazene Diaceturate
  • Toldimfos Sodium
  • Quinapyramine
  • Triclabendazole
  • Albendazole
  • Fenbendazole
  • Oxyclozanide
  • Niclosamide
  • Frusemide
  • Mebendazole

Honey Bee Medicine

  • Pizitol®
  • Apistonic®
  • Transprim®

Human / Veterinary API's

Veterinary API’s

  • Albendazole USP/EP/BP
  • Fenbendazole BP/ EP/BP VET
  • Oxfendazole EP/BP VET
  • Mebendazole USP/EP/BP/POLY 'C'

Human API's 

  •  Pentamidine Isethionate
  •  Ramipril EP / BP
  •  Frusemide USP / EP / BE
  •  Cetrizine DI HCL BP / EP
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×